Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | nuclear factor, erythroid 2-like 2 | Starlite/ChEMBL | No references |
Homo sapiens | polymerase (DNA directed) iota | Starlite/ChEMBL | No references |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0 | 0.5 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0 | 0.5 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0 | 0.5 |
Trypanosoma cruzi | DNA polymerase eta, putative | 0.0023 | 0 | 0.5 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0 | 0.5 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0 | 0.5 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0 | 0.5 |
Mycobacterium ulcerans | DNA polymerase IV | 0.0023 | 0 | 0.5 |
Leishmania major | DNA polymerase kappa, putative | 0.0023 | 0 | 0.5 |
Mycobacterium ulcerans | DNA polymerase IV | 0.0023 | 0 | 0.5 |
Trypanosoma brucei | DNA polymerase eta, putative | 0.0023 | 0 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0023 | 0 | 0.5 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0 | 0.5 |
Trypanosoma brucei | unspecified product | 0.0023 | 0 | 0.5 |
Entamoeba histolytica | hypothetical protein | 0.0043 | 1 | 1 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0 | 0.5 |
Trypanosoma cruzi | DNA polymerase kappa, putative | 0.0023 | 0 | 0.5 |
Mycobacterium tuberculosis | Conserved hypothetical protein | 0.0023 | 0 | 0.5 |
Trypanosoma brucei | DNA polymerase IV, putative | 0.0023 | 0 | 0.5 |
Leishmania major | DNA polymerase eta, putative | 0.0023 | 0 | 0.5 |
Loa Loa (eye worm) | ImpB/MucB/SamB family protein | 0.0023 | 0 | 0.5 |
Trypanosoma cruzi | DNA polymerase kappa, putative | 0.0023 | 0 | 0.5 |
Trichomonas vaginalis | DNA polymerase eta, putative | 0.0023 | 0 | 0.5 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0 | 0.5 |
Trypanosoma brucei | DNA polymerase IV, putative | 0.0023 | 0 | 0.5 |
Giardia lamblia | DINP protein human, muc B family | 0.0023 | 0 | 0.5 |
Trypanosoma brucei | DNA polymerase IV, putative | 0.0023 | 0 | 0.5 |
Schistosoma mansoni | transcription factor LCR-F1 | 0.0043 | 1 | 1 |
Trichomonas vaginalis | DNA polymerase IV / kappa, putative | 0.0023 | 0 | 0.5 |
Trypanosoma cruzi | DNA polymerase kappa, putative | 0.0023 | 0 | 0.5 |
Echinococcus granulosus | Basic leucine zipper bZIP transcription | 0.0043 | 1 | 1 |
Trypanosoma cruzi | DNA polymerase kappa, putative | 0.0023 | 0 | 0.5 |
Leishmania major | DNA polymerase kappa, putative,DNA polymerase IV, putative | 0.0023 | 0 | 0.5 |
Entamoeba histolytica | hypothetical protein | 0.0043 | 1 | 1 |
Entamoeba histolytica | hypothetical protein | 0.0043 | 1 | 1 |
Entamoeba histolytica | hypothetical protein | 0.0043 | 1 | 1 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0043 | 1 | 1 |
Mycobacterium tuberculosis | Possible DNA-damage-inducible protein P DinP (DNA polymerase V) (pol IV 2) (DNA nucleotidyltransferase (DNA-directed)) | 0.0023 | 0 | 0.5 |
Echinococcus multilocularis | Basic leucine zipper (bZIP) transcription | 0.0043 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 2.0596 uM | PUBCHEM_BIOASSAY: Nrf2 qHTS screen for inhibitors. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID493153, AID493163, AID504648] | ChEMBL. | No reference |
Potency (functional) | 2.8184 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Iota. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588623] | ChEMBL. | No reference |
Potency (functional) | = 31.6228 um | PUBCHEM_BIOASSAY: qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature. (Class of assay: confirmatory) | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.